| Literature DB >> 28752128 |
Muhammad Abdul Mabood Khalil1, Jackson Tan2, Taqi F Toufeeq Khan3, Muhammad Ashhad Ullah Khalil4, Rabeea Azmat5.
Abstract
Kidney transplantation (KT) is one of the treatment options for patients with chronic kidney disease. The number of patients waiting for kidney transplantation is growing day by day. Various strategies have been put in place to expand the donor pool. Extended criteria donors are now accepted more frequently. Increasing number of elderly donors with age > 60 years, history of diabetes or hypertension, and clinical proteinuria are accepted as donor. Dual kidney transplantation (DKT) is also more frequently done and experience with this technique is slowly building up. DKT not only helps to reduce the number of patients on waiting list but also limits unnecessary discard of viable organs. Surgical complications of DKT are comparable to single kidney transplantation (SKT). Patient and graft survivals are also promising. This review article provides a summary of evidence available in the literature.Entities:
Year: 2017 PMID: 28752128 PMCID: PMC5511653 DOI: 10.1155/2017/2693681
Source DB: PubMed Journal: Int Sch Res Notices ISSN: 2356-7872
Figure 1Selection criteria for the donors.
| Authors | Journal name/year | Number/surgical technique/immunosuppression used/selection criteria | Outcome |
|---|---|---|---|
| Johnson et al. [ | Journal of Surgery/1996 | 9/Dual kidneys were transplanted intraperitoneally or through bilateral extraperitoneal incision/induction was either with ATG | 100% graft survival at 6 months |
|
| |||
| Remuzzi et al. [ | Journal of American Society of Nephrology/1999 | 24/Bilateral placement through double inguinal incision/Prednisolone, Cyclosporine & mycophenolate mofetil. No comment on induction/Selection Criteria: brain dead donors having 1 of the following• Age > 60 year• History of diabetes or hypertension• Clinical proteinuria (urinary protein excretion rate up to 3 g/24 h) plus renal histopathology score of 4–6 | 100% graft survival at 6 months and 93% at 3 years |
|
| |||
| Lu et al. [ | Archives of Surgery/1999 | 50/Bilateral placement in right and left iliac fossa via midline extra peritoneal approach/Cyclosporine, steroids & MMF | 86% graft survival at 1 year and 76% at 2 years |
|
| |||
| Andrés et al. [ | Transplantation/2000 | 21/Each kidney was implanted extraperitoneally in each iliac fossae/Prednisolone, cyclosporine or tacrolimus and MMF/selection criteria/age greater than 75 or 60–74 and pregraft biopsy showing greater than 15% glomerulosclerosis and lesser than 50% glomerulosclerosis | 95% graft survival at 1 year and 93% at 2 years |
|
| |||
| Gill et al. [ | Transplantation/2008 | 625 received DKT/no comment on surgical technique or immunosuppression/selection criteria: any 2 of the following criteria present: age greater than 60 years, creatinine clearance greater than 65 mL/min, rising serum creatinine greater than 2.5 mg/dL at retrieval, chronic hypertension or type 2 diabetes mellitus, and glomerulosclerosis on biopsy between 15% and 50% | 79.8% graft survival at 3 years |
|
| |||
| Navarro et al. [ | Journal of Urology/2008 | 23 non heart beating DKT/ipsilateral dual transplant, the 2 kidneys from a single donor are implanted into the right iliac fossa with anastomoses to the common (right kidney) and external iliac (left kidney) arterial circulation/no comment on immunosuppression medications/selection criteria: machine perfusion pressure flow index 0.4 mL/min per 100 g/mm Hg and glutathione transferase was greater than 100 IU/L/100 grams renal mass | Glomerular filtration rate at 3 and 6 months was 46.2 & 45.5 ml/minute |
|
| |||
| Snanoudj et al. [ | American Journal of Transplantation/2009 | 81/Allografts were placed either monolaterally or bilaterally, with one or two classical iliac incisions, respectively/received IL-2 receptor antagonist or ATG | Glomerular filtration rate at 12 months 47.8 mL/min |
|
| |||
| Ekser et al. [ | American Journal of Transplantation/2010 | 100/Unilateral extraperitoneal placement via Gibson incision/Induction therapy consisted of antithymocyte globulin (ATG) or Basiliximab. Maintenance immunosuppressive sirolimus or everolimus either without a calcineurin inhibitor (CNI | Glomerular filtration rate at 1 year and 2 years was 115 ± 32 and 128 ± 45 ml/minute |
|
| |||
| Klair et al. [ | American Journal of Transplantation/2013 | 1308/No comment on surgical technique or immunosuppressive medications used/selection criteria: DKT was done in KDRI score 1.4, 1.41–1.8, 1.8–2.2 and greater than 2. DKT showed superior graft survival when KDRI was greater than 2 | Five-year graft survival rates of SKT and DKT by KDRI were as follows: 1.4 (74%, 72%), 1.41–1.8 (63%, 64%), 1.81–2.2 (55%, 59%) and >2.2 (48%, 54%). |
|
| |||
| Frutos et al. [ | Nefrolgia/2012 | 20/Dual kidney transplantation was performed through 2 independent incisions in each of the recipient's iliac fossae/Immunosuppressive medications included induction with basiliximab. Maintenance immunosuppression included prednisolone, tacrolimus & MMF/selection criteria: DKT was done through biopsy scoring plus clinical parameter including Donor's age, medical history, kidney size and creatinine clearance were also considered | Creatinine clearance at 6 months and 1 year was 59.0 ± 18 ml/minute 55.0 ± 18.5 ml/minute |
|
| |||
| Islam et al. [ | Journal of Transplantation/2016 | 29/Extraperitoneal placement in right iliac fossa through curvilinear incision/high risk recipients received ATG and the rest either daclizumab or basiliximab. Maintenance immunosuppression consisted of tacrolimus, MMF, and prednisone/selection criteria: Expanded criteria donors (ECD), defined as deceased donors (1) greater than 60 years old or (2) greater than 50 years old and with at least 2 of the following criteria: (a) a history of hypertension, (b) terminal serum creatinine greater than 1.5 mg/dL, or (c)death due to a cerebrovascular accident | Median e GFR |
. MMF (mycophenolate mofetil), AZA (azathioprine), IL-2 (interleukin-2), ECD (extended Criteria Donor), e GFR (estimated glomerulofilteration rate), ATG (antithymocyte globulin), and SCD (standard criteria donor), OKT3 (muromonab-CD3).
Recipient characteristics DKT versus SKT.
| Author | Journal/year/number of recipient | DKT | SKT | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age | Immunosuppression | Weight | BMI | Comorbid | Age (years) | Weight | BMI | Comorbid | ||
| Remuzzi et al. [ | Journal of American Society of Nephrology/1999/24 DKT | 59.4 ± 9.9 | Prednisolone, Cyclosporine & mycophenolate mofetil. No comment on induction | 71.4 ± 19.1 | 25.3 ± 5.4 | HTN | 50.2 ± 12.1 | 73.1 ± 16.2 | 25.3 ± 4.7 | HTN |
|
| ||||||||||
| Lu et al. [ | Archives of Surgery/1999/50 DKT | 57 ± 11 | Cyclosporine, steroids & MMF | — | — | — | 50 ± 12 | — | — | — |
|
| ||||||||||
| Snanoudj et al. [ | American Journal of Transplantation/2009/81 DKT | 69.4 ± 3.0 | Received IL-2 receptor antagonist or ATG | 68.4 ± 14.1 | 24.3 ± 4.1 | DM | 59.9 ± 6.3 | 72.8 ± 17.0 | 25.1 ± 4.7 | DM |
|
| ||||||||||
| Ekser et al. [ | American Journal of Transplantation/2010/100 DKT | 61.7 ± 5.6 | Induction therapy consisted of antithymocyte globulin (ATG) or Basiliximab. Maintenance immunosuppressive sirolimus or everolimus either without a calcineurin inhibitor (CNI | — | 25.5 ± 3.5 | 57.7 ± 8.6 | — | 24.5 ± 3.4 | — | |
|
| ||||||||||
| Klair et al. [ | American Journal of Transplantation/2013/1308 DKT | 58.9 ±10.5 | No comment on immunosuppressive medications used | — | 25.1 | DM | 49.6 ± 14.8 | — | 29.6 | DM |
|
| ||||||||||
| Bunnapradist et al. [ | Journal of American Society of Nephrology/403 DKT | 55.1 ± 11.5 | No comment on immunosuppressive medications used | 77.1 ± 17.1 | — | — | 48.1 ± 13.7 | 77.4 ± 19.2 | — | — |
. HTN (hypertension), DM (diabetes mellitus), PRA (panel reactive antibody), HLA MM (human leukocyte antigen mismatches), M (male), F(female), MMF (mycophenolate mofetil), AZA(azathioprine), IL-2 (interleukin-2), ATG (antithymocyte globulin), and OKT3 (muromonab-CD3).
Surgical complication of DKT versus SKT.
| Author | Journal/year | DKT | SKT | Significance | |
|---|---|---|---|---|---|
| Surgical technique/number/immunosuppression | Complication | Complications |
| ||
| Frutos et al. [ | Nefrologia/2012 | 20 bilateral Kidney placement through 2 independent incisions in each of the recipient's iliac fossae/induction with basiliximab + prednisolone, tacrolimus & MMF | Hemorrhage 8 (40%) | Hemorrhage 10 (25%) | NSN |
| Lymphocele 3 (15%) | Lymphocele 2 (5%) | SNS | |||
| Resurgery 1 (5%) | Resurgery 1 (2.5%) | NS | |||
| Arterial thrombosis 2 (10%) | Arterial thrombosis 2 (5%) | ||||
|
| |||||
| Snanoudj et al. [ | American Journal of Transplantation/2009 | 81 monolateral or bilateral placement with one or two classical iliac incisions/received IL-2 | Eventration, parietal abscess 6 (7.4%), | Eventration, parietal abscess 8 (11.4%) | NS |
| Ureteral stenosis 9 (11.1%), | Ureteral stenosis 12 (17.1%) | NSN | |||
| Urinary fistula 9 (11.1%) | Urinary fistula 15 (21.4%) | SNS | |||
| Graft artery stenosis 9 (11.1%), | Graft artery stenosis 3 (4.3%) | NSN | |||
| Graft partial infarction 3 (3.7%), | Graft partial infarction 4 (5.7%) | SNS | |||
| Artery thrombosis 5 (6.2%) & | Artery thrombosis 2 (2.9%) | NS | |||
| Vein thrombosis 6 (7.4%) | Vein thrombosis 1 (1.4%) | ||||
| Hemorrhage 10 (12.3%) | Hemorrhage 9 (12.9%) | ||||
|
| |||||
| Remuzzi et al. [ | Journal of American Society of Nephrology/1999 | 24 bilateral placement through double inguinal incision/Prednisolone, Cyclosporine & mycophenolate mofetil | Urinary tract fistula 4 | Urinary tract fistula 1 | — |
| Sepsis from urinary Tract 2 | Sepsis from urinary Tract 2 | — | |||
| Deep vein thrombosis 1 | Deep vein thrombosis 1 | — | |||
| Hematoma 1 | Hematoma 1 | — | |||
| Gastrointestinal Bleeding 1 | Gastrointestinal Bleeding 0 | — | |||
| Bowel occlusion 0 | Bowel occlusion 0 | — | |||
|
| |||||
| Ekser et al. [ | American Journal of Transplantation/2010 | 100 unilateral extraperitoneal placement via Gibson incision/Induction therapy consisted of antithymocyte globulin (ATG) or Basiliximab. Maintenance immunosuppressive sirolimus or everolimus either without a calcineurin inhibitor (CNI |
|
| NS |
|
|
| NSN | |||
|
|
| SNS | |||
|
|
| NS | |||
|
|
| ||||
|
|
| NS | |||
|
| |||||
| Islam et al. [ | Journal of Transplantation/2016 | 29 extraperitoneal placement in right iliac fossa through curvilinear incision/high risk recipients received ATG | Urologic complications 4/29 (14%) | Urologic complications 10/487 (2%) | S |
| All 4 having ureteral stricture | 6 out of 10 have anastomotic strictures and 4 has urine leak | ||||
. IL-2 (interleukin-2), ATG (antithymocyte globulin), MMF (mycophenolate mofetil), and CNI (calcineurin inhibitors).
Outcome of DKT.
| Author | Journal/year/number Of DKT | Number and surgical technique/Immunosuppression for DKT | Delayed graft function | Acute rejection | Graft survival/kidney function (creatinine or GFR) | Patient survival | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| DKT | SKT | DKT | SKT | DKT | SKT | DKT | SKT | |||
| Johnson et al. [ | Transplantation/1996 | Six paired kidneys were placed intraperitoneally, while the remaining four pairs were placed in bilateral retroperitoneal iliac fossa locations/no comment on immunosuppressive medications | — | — | — | — | Overall graft survival of 90.0% and actuarial 1-year graft survival of 83.3%. (no death occurred in cohort) | — | — | — |
| Johnson et al. [ | Dual kidneys were transplanted intraperitoneally or through bilateral extraperitoneal incision/Induction was either with ATG | — | — | — | — | Graft survival at 6 month in dual was 100% (no death till 6 month) in <50 years cadaveric kidney donor and 75% graft t survival (no comment whether death censored or not) in recipient who got kidney from cadaveric donor age > 60 years | 62.5 ± 5.4 & 24.5 ± 5.3 ml/minute in age < 50 & age > 60. Graft survival 95% in age < 50 & 75% survival in age > 60 years | 100% in recipient of cadaveric kidneys from less than 50 year & 83% from donor greater than 60 years | 95% & 83% | |
|
| ||||||||||
| Alfrey et al. [ | Transplantation/1997 | 20 DKT as two single kidneys on the back table. Through a midline incision the iliac vessels were exposed via extraperitoneal dissection/all patients received cyclosporine-based triple-drug therapy | 9% | 45% | 87% survival at 1 year (nondeath censored. Graft loss defined as return to dialysis or death) | Cr 2.8 ± 2.0 mg/dl at 4 weeks & 81% survival at 1 year | Cr .4 ± 0.5 mg/dl at 4 weeks & 93% survival at 1 year | 96% | ||
|
| ||||||||||
| Stratta and Bennett [ | Transplant Proc/1997 | 60 DKT (25 young donors 35 old donors)/No comments on surgical teqhnique or immunosuppressive medications used | — | — | — | — | 90.8% 1 year survival (No comment whether death censored or not) | 87.5% 1 year survival | — | — |
|
| ||||||||||
| Lu et al. [ | Archives of Surgery/1999 | 50 bilateral placement in right and left iliac fossa via midline extra peritoneal approach/Cyclosporine, steroids & MMF or AZA. Induction with OKT3 or IL-2 inhibitor | 26% | 39% | 0.2 ± 0.5 | 0.7 ± 0.9 | Death censored graft survival at 2 years was 85% | Death censored graft survival at 2 years was 84%. years in ECD SKT and 86% in control single | 86% 2-year survival | 96% 2-year survival |
|
| ||||||||||
| Remuzzi et al. [ | Journal of American Society of Nephrology/1999 | 24 bilateral placement through double inguinal incision/Prednisolone, Cyclosporine & mycophenolate mofetil. No comment on induction | 20.8% | 20.8% | 20.8% | 18.8% | Cr 1.5 ± 0.4 mg/dl & 100% Survival at 6 months (no death till follow-up) | Cr 1.9 ± 0.7 mg/dl 100% Survival at 6 months | 100% Survival at 6 months | 100% survival at 6 months |
|
| ||||||||||
| Jerius et al. [ | Journal of Urology/2000 | 28 kidneys were placed bilaterally or unilaterally using standard right and left lower quadrant extraperitoneal approaches/4 patients receiving pancreas received OKT3 induction. Triple drug immunosuppression consisted of cyclosporine or tacrolimus, azathioprine or mycophenolate mofetil and prednisone was used | 6 out 28 cases | 7 out of 31 cases | — | — | In an intent to treat analysis with inclusion of all patients 1 and 2-year graft survival rates were 93% and 86%. These differences were not statistically significant. The data were then adjusted to eliminate nongraft dependent loss factors. The patient in each group with loss due to subacute humoral rejection was excluded from analysis. The graft loss due to patient noncompliance in group 1 was treated as censored data at the time of loss instead of graft failure. With these adjustments 1- and 2-year graft survival rates for DKT were 96% and 96% which was significantly better than SKT | 1- and 2-year graft survival rates of 77% and 73% | — | — |
|
| ||||||||||
| Lee et al. [ | Journal of American College of Physician/1999 | 41 dual kidneys were procured in the usual fashion and were prepared as 2 single kidneys on the back table. Through a midline incision the iliac vessels were exposed by extraperitoneal dissection; one kidney was anastomosed to the left iliac vessels, and the other to the right iliac vessels/the majority of the recipients transplanted received cyclosporine based triple therapy that included mycophenolate mofetil and prednisone | 24% | 33% | — | — | GFR at 1 year 54 ± 23 ml/min & 1 year graft survival 89% (graft loss defined as permanent return to dialysis) | GFR at 1 year 57 ± 25 ml/min 1-year graft survival 90% | 1-year patient survival 97% | 1-year patient survival 98% |
|
| ||||||||||
| Gill et al. [ | Transplantation/2008 | 625 received DKT/no comment on surgical technique or immunosuppression | 29.3% | 33.6% ECD | 12.1% at 1 year | 17.6% at 1 year | Death-censored allograft survival of DKT and ECD transplants were not significantly different up to 4 years after transplant | Death-censored allograft survival of DKT and ECD transplants were not significantly different up to 4 years after transplant | — | — |
|
| ||||||||||
| Snanoudj et al. [ | American Journal of Transplantation/2009 | 81 monolateral or bilateral placement with one or two classical iliac incisions/received IL-2 | 31.6% | 51.4% (Significant) | 12.3% at 1 year | 34.3% at 1 year | Kaplan–Meier estimates of non-death-censored graft survival up to 3 years similar | Kaplan–Meier estimates of non- death-censored graft survival up to 3 years similar | Kaplan–Meier estimates of patient survival similar up to 3 years | Kaplan–Meier estimates of patient survival similar up to 3 years |
|
| ||||||||||
| Frutos et al. [ | Nefrologia/2012 | 20 bilateral Kidney placement through 2 independent incisions in each of the recipient's iliac fossae/induction with basiliximab + prednisolone, tacrolimus & MMF | 30% | 35% | — | — | GFR at 1 year 55.0 ± 18.5. Graft survival at 3 years was 90% (not death censored). | GFR at 1 year 51.3 ± 6.2 | — | — |
|
| ||||||||||
| Ekser et al. [ | American Journal of Transplantation/2010 | 100 unilateral extraperitoneal placement via Gibson incision/Induction therapy consisted of antithymocyte globulin (ATG | 31% | 30% | 17% | 28% | Actuarial Kaplan–Meier graft survival curves at 5-year follow-up was 90.9% (no comment about death censored or not death censored) | 4 GFR at 5 year 9 ± 13 (12 patients) | 5-year patient survival, 95.6% | 5-year patient survival, 87.3% |
|
| ||||||||||
| Islam et al. [ | Journal of Transplantation/2016 | 29 extraperitoneal placement in right iliac fossa through curvilinear incision/high risk recipients received ATG and the rest either daclizumab or basiliximab. | 10.3% | 9.2% | 20.7% | 22.4% | Median e GFR (IQR) at 36 months 45.9 ml/minute (36.8–62.6). Actuarial graft survivals 93% at 3 years (No death occurred in this cohort) | Median e GFR (IQR) at 36 months 56.7 (43.7–71.8) | Actuarial patient survivals 100% at 3 years | |
. IL-2 (interleukin-2), ATG (antithymocyte globulin), MMF (mycophenolate mofetil), AZA (azathiopurine), CNI (calcineurin inhibitors), ECD (extended criteria donor), e GFR (estimated glomerulofilteration rate), and GFR (glomerulofilteration rate).